Abstract. Pancreatic cancer has a poor prognosis.
Introduction
Pancreatic cancer has a poor prognosis with a 5-year survival of <5% and the fourth most deadly cancer (1) . The poor prognosis of pancreatic cancer is associated with its chemotherapy resistance and early metastasis (2, 3) . Hence, the high mortality of pancreatic cancer indicates a requirement for early detection and novel therapies.
The PI3K/Akt pathway, a survival signaling pathway, is involved in the control of cell apoptosis and proliferation and >50% human cancers are related to the deregulation of this pathway, including pancreatic cancer (4) (5) (6) (7) . Akt contributes to cell plasticity in pancreas as a regulator and its overexpression has been proved to be a common phenomenon in pancreatic cancer (8) (9) (10) (11) . Therefore, the PI3K/Akt pathway plays a crucial role in the development of pancreatic cancer.
Polo-like kinase 1 (Plk1), a serine/threonine kinase, plays an important role in cell cycle and apoptosis (12) . Plk1 is overexpressed in various tumors and its overexpression is associated with poor prognosis (12, 13) . Plk1 overexpression is a common and early event and contributes to gemcitabine resistance in pancreatic cancer (14, 15) .
Apoptosis occurs in multicellular organisms as a programmed cell death and it can be activated through intrinsic pathway and extrinsic pathway (16) . The intrinsic pathway involves the mitochondria (17) . Activation of caspases is an important process for the intrinsic pathway and is controlled by anti-or pro-apoptotic proteins, such as XIAP, Bcl-2 and BAX (18, 19) .
In cell cycle, PI3K/Akt-dependent phosphorylation of Plk1-Ser99 is required for metaphase-anaphase transition and Plk1-dependent phosphorylation of IRS2-S556 inhibits mitotic exit through reducing Akt activity (20, 21) . However, the mechanism of cell apoptosis induced by PI3K/Akt pathway and Plk1 still remains unclear.
In this study, we investigated the function of PI3K/Akt pathway on cell proliferation and apoptosis in pancreatic carcinoma in vitro and in vivo and the effect of Plk1 in this process. Our results could help to understand apoptosis-related pathway, such as caspase-related or Bcl-2 family-mediated pathway, and benefit the therapy of pancreatic cancer.
Materials and methods
Cell culture and antibodies. Human pancreatic cancer cell lines (AsPC-1, BxPC-3, PANC-1) were acquired from ATCC (Manassas, vA, USA) and maintained in RPMI-1640 medium (Gibco, Gaithersburg, MD, USA), supplemented with 100 U/ml penicillin, 100 U/ml streptomycin, and 10% fetal bovine serum (FBS) (Gibco) at 37˚C in 5% CO 2 . Antibodies against p-Akt, Akt, Plk1, XIAP, caspase-3, cleaved caspase-3 were purchased from Cell Signaling Technology (Beverly, MA, USA) for western blot analysis. Antibodies against Bcl-2, BAX were purchased from Abcam (Abcam, UK) for western blot analysis. Akt antibody for immunohistochemistry (IHC) was purchased from Abcam (Abcam). GAPDH and actin antibodies for western blot analysis were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunohistochemistry (IHC) and tissue microarray.
The pancreatic cancer tissue microarrays were purchased from Xian Ailina Biotechnology Co., Ltd. (Xian Ailina Biotechnology Co., Ltd., China). The expression of Akt was measured by IHC as described (22) . Akt staining in human tissues were scored independently by two pathologists, by evaluating a semiquantitative immunoreactivity score (IRS) as described (23) . Then, tissues with IRS 0-5 and IRS 6-9 were defined as low and high expression of Akt, respectively.
Short hairpin RNA. The short hairpin RNA for Plk1 (shPlk1) and empty vector (Ev) was synthesized with the vector pYr-1.1 (hU6/EGFP/Neo) (Changsha Yingrun Biotechnology Co., Ltd., China). Cell HEK 293 (ATCC, USA) was used to pack recombination adenovirus and the empty vector (Ev) was constructed as an experimental control. Western blot analysis. Cells were washed in cold PBS twice, then solubilized in RIPA lysis buffer (vazyme, Nanjing, China). Samples with the same amount of protein were analyzed by western blotting as described (24) . , 12 nude mice were divided into two groups (control group, LY294002 group) randomly. The LY294002 group was injected with LY294002 (25 mg/kg/d; dissolved in DMSO) via the abdominal route; and the control group was treated with equal 1% DMSO via the abdominon. Tumor volume was observed every 2 days and was calculated by the formula: (length x width 2 )/2. Mice were sacrificed at day 12 and the weight and volume of the tumors were measured. Then the tumor along the maximum transverse incision was cut in half: one half was made into paraffin block after fixation in 4% neutral formaldehyde and the other half was cryopreserved at -80˚C. All animals received human care and all experiments were carried out according to the guidelines outlined in the Guide for the Care and Use of Laboratory Animals.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.
Paraffin blocks were cut into slices with 4 µm thickness. The TUNEL Brighted Apoptosis Detection kit (vazyme) was used to detect cellular apoptosis in tumor tissues according to the instructions.
Statistical analysis. All statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Each experiment was performed three times. All data were expressed as mean ± SD unless otherwise specified. Data from each group were statistically analyzed using a two-tailed Student's t-test, except immunohistochemical score which was analyzed by Chi-square test. Differences were considered statistically significant at P<0.05. P-values of the statistical significances for differences were set as 
Results
Akt is overexpressed in pancreatic cancer. Immunohistochemistry staining was used to detect the expression of Akt in pancreatic cancer. The staining of pancreatic tissue microarray (including 51 cases of normal pancreas and 91 cases of pancreatic cancer) showed that 27% of normal tissues had Akt positive staining (88% with low expression, IRS 0-5; 12% with high expression, IRS 6-12), whereas 59% of tumor tissues had Akt positive staining (71% with low expression, IRS 0-5; 29% with high expression, IRS 6-12) (Fig. 1A and B, Table I ). The expression of Akt in tumor tissues was significantly higher than it in normal tissues (P<0.05).
Correlation of Akt levels with clinical characteristics.
According to the study of the relationship between the expression level of Akt in pancreatic cancer tissues and the clinical characteristics of these patients, there was no significantly difference among gender, age or clinical stage. However, Akt expression level was correlated with pathologic grade and there were more cancer tissues with Akt high expression in grade 3 than those in grade 1-2 (grade 1-2 with 79% low expression and 21% high expression of Akt; grade 3 with 57% low expression and 43% high expression of Akt; P<0.05) (Fig. 1C and Table II) .
Inhibition of the PI3K/Akt pathway could reduce cell proliferation and induce apoptosis in pancreatic cancer cells in vitro.
Cell proliferation influenced by different concentrations of LY294002 was detected by MTT assay (Fig. 2A) . The optimal concentrations of LY294002 for different pancreatic cancer cell lines were IC50 AsPC-1 =40 µM, IC50 BxPC-3 =15 µM and IC50 PANC-1 =35 µM, respectively. Then qRT-PCR showed LY294002 had no effect on mRNA level of Akt (Fig. 2B) . While protein level of p-Akt was downregulated and it suggested that Table I . Expression of Akt in human pancreas and pancreatic cancer. LY294002 influenced PI3K/Akt pathway through decreasing phosphorylation of Akt (Fig. 2C) . As described previously, the PI3K/Akt pathway is an important survival signaling pathway in pancreatic cancer and it is supposed to be related to cell apoptosis in pancreatic cancer. Compared to the control group, using LY294002 to block PI3K/Akt pathway it could induce significant apoptosis (P<0.001) ( Fig. 2D and E) . Then we detected the expression level of apoptosis-related proteins such as XIAP, Bcl-2, BAX and caspase-3 by western blotting and found that both caspase-dependent signaling pathway (downregulating XIAP and upregulating cleaved caspase-3) and Bcl-2 family mediated signaling pathway (downregulating Bcl-2 and upregulating BAX) contributed to the apoptosis induced by LY294002 (Fig. 2C) . That means PI3K/Akt pathway can control cell survival through several routes and LY294002 might become an ideal drug to induce cancer cell apoptosis.
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Plk1 plays a crucial role in the pancreatic cancer cell apoptosis induced by PI3K/Akt pathway inhibition.
Plk1 is essential for cell cycle regulation and our previous study showed Plk1 overexpression is correlated to cell proliferation and chemotherapy resistance in pancreatic cancer (25) . As PI3K/Akt pathway is reported to be linked to anti-apoptotic signal transduction and chemoresistance of pancreatic cancer (26, 27) , the relationship between Plk1 and PI3K/Akt pathway is worthy of study and concern. Then we constructed recombinant adenovirus rAd-Plk1-shRNAs (shPlk1) to further confirm the effect of Plk1 in the process of apoptosis induced by PI3K/Akt pathway inhibition. LY294002 can downregulate Plk1 mRNA level as well as Plk1 protein level (P<0.01) (Fig. 3A and B) while Plk1 suppression has no influence on the expression of Akt (Fig. 3C and D) . Flow cytometry showed Plk1 knockdown could induce significant apoptosis in pancreatic cancer cells as cancer cells infected with shPlk1 for 48 h had obviously higher apoptosis rate than the Ev group (P<0.01) (Fig. 3E and F) . We also found that Plk1 knockdown induced cancer cell apoptosis through downregulating XIAP, Bcl-2 and upregulating cleaved caspase-3 and BAX (Fig. 3D ). Thus as a result, we believe that LY294002 could activate apoptosis-related pathway, such as caspase-related or Bcl-2 family-mediated pathway through downregulating Plk1. ; P<0.01) and the weight (1,025±161 vs 449±65 mg; P<0.01) of LY294002 group were significantly less than the control group (Fig. 4A-C) . Hematoxylin-eosin staining showed more necrosis and higher expression of cleaved caspase-3 in LY294002 group (Fig. 4D) . TUNEL assay revealed LY294002 induced pancreatic cancer cell apoptosis in the tumor xenograft model (Fig. 4E) . All the data above indicated that inhibition of PI3K/Akt pathway could suppress pancreatic cancer growth and induced tumor necrosis and cell apoptosis in vivo.
Discussion
Pancreatic cancer is a malignant tumor with 5-year survival <5%, despite years of efforts, ~80% of patients have locally advanced or metastatic disease when they are diagnosed (28) .
PI3K/Akt pathway is important in the development and progression of pancreatic cancer and its activation is a common event during this process (29) (30) (31) . Schlieman et al (10) found activation of Akt existed in half of pancreatic cancer cases, which is consistent with the result of our study. Our study also revealed that the expression level of Akt was closely related to the pathologic grade of pancreatic cancer (Table II) . Thus, inhibition of PI3K/Akt pathway could be a potential therapeutic target for the treatment of pancreatic cancer. Kim et al (32) showed Akt inhibition could enhance chemosensitivity of gemcitabine in pancreatic cancer, Bondar et al (33) and our study showed inhibition of PI3K/Akt pathway induces cell apoptosis and reduces cell proliferation in pancreatic cancer, but the mechanism of this process is unclear.
Apoptosis plays an important role in the growth and development of mammals and its deregulation results in many diseases, especially tumorigenesis (34) (35) (36) . There are two apoptosis pathways: intrinsic pathway and extrinsic pathway. Most apoptosis are induced by the intrinsic pathway which is activated by intracellular signals generated such as caspase signaling pathway when cells are stressed (37) . It is reported that XIAP is phosphorylated by Akt at residue serine 87 in vitro and in vivo and this process results in resistance to cisplatin-induced XIAP degradation, caspase-3 activation, and apoptosis (38) . Our study showed similar results that XIAP was downregulated and cleaved caspase-3 was upregulated after PI3K/Akt pathway was inhibited by LY294002 in pancreatic cancer. Moreover, we explored whether Bcl-2 family mediated apoptosis is related to PI3K/Akt pathway inhibition and found Bcl-2/BAX ratio was decreased after pancreatic cancer cells were treated with LY294002, indicating that PI3K/Akt pathway inhibition can induce cancer cell apoptosis by activating Bcl-2 family-mediated apoptosis pathway.
As described previously, both PI3K/Akt pathway and Plk1 play an important role in the development, progression and chemoresistance of pancreatic cancer and PI3K/ Akt-dependent phosphorylation of Plk1-Ser99 is required for metaphase-anaphase transition (20, (25) (26) (27) . Our previous study revealed Plk1 knockdown could lead to cell cycle arrest and enhance chemosensitivity to gemcitabine in pancreatic cancer.
Our present study indicated that Plk1 knockdown could induce apoptosis in pancreatic cancer through downregulating XIAP, Bcl-2 and upregulating cleaved caspase-3 and BAX. At the same time, PI3K inhibitor LY294002 downregulated Plk1 and induce apoptosis. It means that PI3K/Akt pathway inhibition can induce cancer cell apoptosis through activating the caspase pathway and decreasing Bcl-2/BAX ratio via suppression of Plk1 expression.
In conclusion, this study implied that PI3K/Akt pathway inhibition could suppress cell proliferation and lead to cell apoptosis in pancreatic cancer. Apoptosis induced by PI3K/Akt pathway inhibition is correlated with the expression of Plk1 and downregulating Plk1 can activate apoptosis-related pathway, such as caspase-related and Bcl-2 family-mediated pathway. These results indicate that combination therapy, especially targeting to PI3K/Akt pathway might be an achievable access for the treatment of pancreatic cancer.
